Skip to content
Peptide research

DS (Asp-Ser)

Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

A Khavinson-family dipeptide (aspartic acid, serine) marketed for neuroprotection and healthy brain aging. The case rests on an epigenetic mechanism and animal data; human evidence is speculative, with no clinical trials. No adverse effects are reported, but human safety data for DS itself is essentially absent, and unregulated sourcing raises purity concerns. Not an approved drug in the US; sold only as a research-grade product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

DS5 is an ultrashort synthetic peptide made of just two amino acids (aspartic acid and serine), developed within the Khavinson peptide bioregulation framework in Russia. It is derived from Cortexin, a brain-tissue-based preparation, and is studied for its potential to protect nerve cells. DS5 is sometimes marketed under the name Vesselget for blood vessel protection, though the primary published research focuses on its brain-protective properties. It is one of approximately 15 ultrashort peptides developed by Vladimir Khavinson's research group.

How it works in the body

A dipeptide bioregulator that targets brain tissue. Modeling predicts histone H1.3 binding. Changes in chromatin, Fkbp1b expression and calcium homeostasis are proposed downstream effects.

Research overview

DS5 is theorized to work by binding to a histone protein (a structural protein that packages DNA), which alters how DNA is arranged at a specific gene region. This proposed change might affect a gene involved in neuronal calcium regulation — and calcium imbalance is a key driver of neurodegenerative diseases like Alzheimer's. A 2022 review further explored how DS5's ability to "open up" DNA regions could help counteract the calcium-related damage seen in Alzheimer's disease. However, the published evidence on DS5 specifically is very limited, consisting primarily of computer modeling and cell studies rather than animal or human trials. No human clinical trials have been published in Western peer-reviewed literature.

Who researches DS (Asp-Ser)?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching neuroprotection via epigenetic modulation

    One of the primary studied benefits of DS (Asp-Ser).

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • No specific adverse effects have been reported for DS dipeptide in published literature

    Low

    Absence of DS toxicology/clinical literature on PubMed/PMC; the modeling paper reports no in vivo exposure

  • Khavinson peptide bioregulators as a class are reported to lack toxic, allergic, or adverse effects in experimental and clinical studies

    Low

    Khavinson-group geroprotector/bioregulator clinical review literature (self-reported class safety).

  • Very limited safety data specific to DS — most safety data comes from the broader Khavinson peptide class

    Moderate

    No DS-specific safety study located in PubMed/PMC; class-only sourcing as described above

  • No long-term human safety studies have been conducted for DS specifically

    Moderate

    Absence in ClinicalTrials.gov and PubMed searches (negative finding, not a positive citation)

  • As with all research peptides, purity and sourcing are critical concerns; unregulated products may contain contaminants

    High

    FDA bulk drug substances for compounding (nominated substances / category listings), https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding — supports the unapproved/unstandardized status; it does not itself document DS-specific testing

  • Theoretical risk of unintended epigenetic modifications given the chromatin-modulating mechanism, though not observed in available studies

    Theoretical

    Proposed mechanism from the 2019 DS-H1.3 modeling study; no off-target or genome-wide profiling published

Interaction summary(7)

Rated by direction with this peptide

  • Tacrolimus (FK506) and sirolimus/everolimus

    CautionTheoretical

    These immunosuppressants act through FKBP12/FKBP1b, the protein DS is hypothesized to affect via chromatin change at the Fkbp1b locus, so an altered FKBP1b pool could in principle shift free-drug/target stoichiometry. Entirely mechanistic: the DS effect on FKBP1b has never been measured, no interaction study exists, and no clinical case has been reported. Flagged only because these drugs have narrow therapeutic indices.

    FKBP12 as the tacrolimus/sirolimus binding protein (established pharmacology, drug labels); DS-Fkbp1b link is hypothesis from the 2019 modeling study only

  • Dantrolene and other ryanodine-receptor / intracellular Ca2+-release modulators

    CautionTheoretical

    FKBP1b stabilizes RyR and IP3R channels governing ER/SR calcium release, so a peptide hypothesized to modulate FKBP1b expression sits nominally on the same pathway. Direction and magnitude of any combined effect are unstudied and the upstream DS effect is unverified; this is a pathway adjacency, not a documented interaction.

    FKBP1b/RyR biology from general calcium-signaling literature; no DS interaction data exist

  • Cortexin (bovine cerebral cortex polypeptide complex)

    NeutralTheoretical

    DS was synthesized as a fragment/derivative of cortexin, so co-use is redundant rather than additive — overlapping rather than independent activity. No combination study has been performed and no synergy has been demonstrated, so Synergistic overstated the evidence.

    DS described as cortexin-derived in the 2019 Khavinson-group paper; no combination study published

  • Other Khavinson ultrashort peptides (EDR/Pinealon, KED, AEDG/Epitalon)

    NeutralTheoretical

    EDR and AEDG are described as binding linker histones (H1.3, H1/3, H1/6), the same class of site proposed for DS. Convergence on a shared binding site is at least as likely to be competitive or simply redundant as synergistic, and no combination study of any of these peptides has been performed. Calling it Synergistic asserted a direction the data cannot support.

    Khavinson-group ultrashort-peptide/histone-binding modeling literature (Molecules 2021 review; Mol Biol 2019); no combination studies

  • Memantine and cholinesterase inhibitors (donepezil, rivastigmine)

    NeutralTheoretical

    No pharmacokinetic or pharmacodynamic overlap has been demonstrated: a dipeptide hypothesized to act on chromatin has no established relationship to NMDA-channel blockade or acetylcholinesterase inhibition. Listed because co-use in dementia populations is plausible and entirely unstudied, not because an interaction is suspected.

    No published interaction data (negative finding); mechanisms non-overlapping on current understanding

  • Calcium channel blockers (verapamil, nifedipine, amlodipine)

    NeutralTheoretical

    The proposed DS effect concerns intracellular ER/SR calcium release via FKBP1b, not plasma-membrane L-type channels, so a direct interaction is unlikely; the shared word 'calcium' is not evidence of overlap. Included to pre-empt that confusion.

    Mechanistic distinction between intracellular Ca2+ release and L-type channel blockade; no interaction studies of DS

  • CYP450 substrates and inhibitors generally

    NeutralTheoretical

    Nothing here is measured. Dipeptides are cleared by peptidases rather than hepatic oxidative metabolism, so clinically meaningful CYP-mediated interactions are not expected — but this is inference from general peptide pharmacology, as no ADME study of Asp-Ser has been published.

    General peptide ADME principles; no DS-specific pharmacokinetic data located

Known risks(6)

  • No specific adverse effects have been reported for DS dipeptide in published literature

  • Khavinson peptide bioregulators as a class are reported to lack toxic, allergic, or adverse effects in experimental and clinical studies

  • Very limited safety data specific to DS — most safety data comes from the broader Khavinson peptide class

  • No long-term human safety studies have been conducted for DS specifically

  • As with all research peptides, purity and sourcing are critical concerns; unregulated products may contain contaminants

  • Theoretical risk of unintended epigenetic modifications given the chromatin-modulating mechanism, though not observed in available studies

Drug interactions(5)

  • No specific drug interactions have been documented for DS (Asp-Ser) dipeptide in published literature

    No interaction data available

  • Theoretical interaction with drugs affecting calcium channel signaling given DS's mechanism involving Ca2+ homeostasis

    No interaction data available

  • May theoretically interact with immunosuppressants (e.g., FK506/tacrolimus) given its regulation of FKBP1b — the FK506-binding protein

    No interaction data available

  • No known interactions with common cardiovascular medications, though caution is warranted due to its vasoprotective classification

    No interaction data available

  • As a dipeptide, DS is expected to have minimal systemic pharmacokinetic interactions due to rapid degradation by peptidases

    No interaction data available

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
3
Human Studies
0

Evidence for DS dipeptide is limited to molecular modeling (in silico) studies and broader class-level preclinical data from the Khavinson bioregulator research program. No specific human clinical trials for the DS dipeptide have been published in Western peer-reviewed journals. The parent compound Cortexin has undergone clinical trials in Russia for cerebrovascular disorders and brain injuries.

Researched for(4)

Rated by confidence in the evidence

  • Neuroprotection via epigenetic modulation

    Speculative

    Based on molecular modeling of DS binding histone H1.3, not tested in cells or animals.

    Kuznik/Davydov/Khavinson, Mol Biol (Mosk) 2019;53(2):299-307 (modeling study); review restatement: PMC9032300

  • Calcium homeostasis regulation in neurons

    Speculative

    Inferred from a proposed gene target linked to calcium signaling, not measured directly for DS.

    Mol Biol 2019 modeling paper (DS-H1.3 docking); FKBP12/RyR biology from general FKBP literature, not from any DS experiment

  • Potential Alzheimer's disease-relevant neuroprotection

    Speculative

    Alzheimer's relevance is extrapolated from related peptides in reviews, not from DS-specific studies.

    Review context: IJMS 2022 neuroepigenetics-of-ultrashort-peptides review (PMC9032300). No DS-specific Alzheimer's disease source exists.

  • Gene expression regulation through peptide-histone interactions

    Speculative

    Computational docking suggests histone binding; no gene-expression or protein data confirm this for DS.

    Mol Biol 2019 DS-H1.3 docking study; class context: Khavinson & Popovich ultrashort-peptide review, Molecules 2021

Benefits(5)

  • Neuroprotection via epigenetic modulation

    Modeling predicts DS–histone H1.3 binding; altered chromatin and protein synthesis remain proposed mechanisms (Kuznik et al., 2019).

  • Calcium homeostasis regulation in neurons

    Proposed DS-mediated Fkbp1b activation could influence neuronal calcium regulation; these effects have not been demonstrated by the cited modeling.

  • Potential Alzheimer's disease-relevant neuroprotection

    DS-mediated euchromatin activation may counteract Ca2+-mediated neurodegenerative processes implicated in AD pathogenesis (Ilina et al., 2022, Int J Mol Sci)

  • Vasoprotection and vascular system support

    Classified as Vesselget (Cytogen) targeting the vascular system in the Khavinson bioregulator classification; limited direct published evidence for vascular effects of DS specifically

  • Gene expression regulation through peptide-histone interactions

    Part of a broader class of ultrashort peptides shown to interact with histones and DNA to modulate gene expression patterns (Khavinson peptide bioregulation framework, multiple publications 2013-2022)

Key studies(3)

  1. Epigenetic Mechanisms of Peptide-Driven Regulation and Neuroprotective Protein FKBP1b

    Molecular modeling / in silico studyN/A (computational study)

    Kuznik BI, Davydov SO, Popravka ES, Lin'kova NS, Kozina LS, Khavinson VKh

    Molecular Biology (Moscow)

    2019

    Modeling predicts DS and EDR binding to histone H1.3; downstream Fkbp1b transcription and calcium effects are hypotheses.

  2. Ilina A, Khavinson V, Linkova N, Petukhov M

    International Journal of Molecular Sciences

    2022

    EDR and DS peptides bind to histone H1.3, and activation of Fkbp1b gene transcription through DS-mediated euchromatin activation can regulate calcium homeostasis in neurons, essential for counteracting Ca2+-mediated neurodegenerative processes in Alzheimer's disease.

  3. Peptide Regulation of Gene Expression: A Systematic Review

    Systematic reviewN/A (review of multiple studies)

    Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR

    Molecules

    2021

    DS is listed among neuroprotective peptides that can bind to histone H1.3. Short peptides regulate gene expression through interactions with histones, DNA regulatory elements, and effector molecules, representing epigenetic mechanisms of peptide bioregulation.

Regulation & availability

Why researchers look at it

Molecular modeling suggests this two-amino-acid peptide modifies histone structure to reactivate genes controlling calcium homeostasis in neurons — a process directly implicated in Alzheimer's pathology. Among the least-studied bioregulator peptides, with only computational and cell-level data and no animal or human trials. It remains a theoretical proof-of-concept rather than a practical intervention.

FDA status
Not FDA-approved. DS (Asp-Ser) has no regulatory approval from the FDA, EMA, or other Western regulatory bodies. It is not listed in the FDA's bulk drug substances categories. The parent compound Cortexin is approved as a pharmaceutical in Russia and some CIS countries for neurological conditions but has no Western regulatory approval. DS is sold as a dietary supplement or research compound in markets where it is available.
WADA status
DS is not individually named on the 2026 WADA Prohibited List. Section S0 prohibits pharmacological substances without governmental approval for human therapeutic use, unless covered elsewhere on the List. If DS has no such approval, S0 applies at all times; an individual listing or adjudication is not required.
Prescribability
Not prescribable in the US or EU. DS (Asp-Ser) is not FDA-approved and has no regulatory approval outside of Russia/CIS countries. Cortexin, the parent polypeptide complex from which DS was derived, is a registered pharmaceutical in Russia.
Availability
Very limited availability. The parent compound Cortexin is a registered pharmaceutical in Russia. DS is typically supplied in capsule form as part of the Cytogen range.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(6)

  1. 1980s
    Vladimir Khavinson begins developing peptide bioregulators at the Saint Petersburg Institute of Bioregulation and Gerontology for Soviet military and space applications
  2. 1999
    Cortexin (the parent polypeptide complex from which DS was derived) is approved as a pharmaceutical in Russia for neurological conditions
  3. 2014
    Khavinson and Kuznik publish comprehensive review classifying peptide bioregulators as a new class of geroprotectors
  4. 2019
    Kuznik et al. publish key study on DS and EDR peptides' epigenetic mechanisms via histone H1.3 binding and FKBP1b regulation (Molecular Biology, Moscow)
  5. 2021
    Systematic review of peptide regulation of gene expression includes DS among neuroprotective peptides (Khavinson et al., Molecules)
  6. 2022
    Ilina et al. review neuroepigenetic mechanisms of ultrashort peptides in Alzheimer's disease, contextualizing DS mechanism (Int J Mol Sci)

Sources & FAQs

Research sources(5)

  1. Kuznik BI et al. (2019) Molecular Biology (Moscow) 53(2):339-348. PMID: 31099784
  2. Ilina A et al. (2022) Int J Mol Sci 23(8):4259. doi: 10.3390/ijms23084259
  3. Khavinson V et al. (2021) Molecules 26(22):7053. Systematic review of peptide gene regulation
  4. Bioregulators.info — Khavinson Peptide Bioregulators Interactive Guide
  5. Khavinson V, Kuznik B (2013) Peptide bioregulators: A new class of geroprotectors

Frequently asked questions(5)

What is DS5 / DS peptide?

DS is an ultrashort synthetic dipeptide consisting of aspartic acid and serine (Asp-Ser), developed as part of the Khavinson peptide bioregulator research program. It is derived from Cortexin, a clinically approved cerebral cortex polypeptide complex. The '5' in DS5 may refer to a dosage formulation. It is also known as Vesselget in the Cytogen product line.

How does DS peptide work?

Modeling predicts DS–histone H1.3 binding. Effects on Fkbp1b transcription and neuronal calcium remain hypotheses.

Is there clinical evidence for DS peptide in humans?

No human clinical trials specific to the DS dipeptide have been published in Western peer-reviewed literature. Evidence is limited to molecular modeling (in silico) studies and class-level preclinical data. The parent compound Cortexin has undergone clinical trials in Russia.

What is the difference between DS and EDR (Pinealon)?

Both DS (Asp-Ser) and EDR (Glu-Asp-Arg / Pinealon) are cortexin derivatives with neuroprotective activity that bind to histone H1.3. EDR is a tripeptide with considerably more published research, while DS is a dipeptide with more limited data. EDR is widely marketed as Pinealon; DS is marketed as Vesselget.

Is DS peptide the same as Vesugen?

No. DS (Asp-Ser) and Vesugen (KED / Lys-Glu-Asp) are different peptides. Both target the vascular system in the Khavinson framework, but they have different amino acid sequences and different research profiles. Vesugen (KED) has significantly more published clinical data.